Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924402 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
A Phase 1 study of Chronic Lymphocytic Leukemia and B Cell Non-Hodgkin's Lymphoma, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
- 20
- Study locations
NCT02924402: Completed Phase 1 study of Chronic Lymphocytic Leukemia and B Cell Non-Hodgkin's Lymphoma, sponsored by Xencor.
NCT02924402 is a Phase 1 study of Chronic Lymphocytic Leukemia and B Cell Non-Hodgkin's Lymphoma that has completed, run by Xencor. The registered enrollment target is 154 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02924402, a Phase 1 study of Chronic Lymphocytic Leukemia and B Cell Non-Hodgkin's Lymphoma, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
Conditions Studied
Interventions
- BIOLOGICAL XmAb13676
Study Locations (20)
Other
- Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest - Bordeaux
- Hopital Henri Mondor - Créteil
- Institut Paoli Calmette Dpt of Oncology/Hematology - Marseille
- Chu Montpellier, Hematologie Clinique St. Eloi - Montpellier
- CHU de Nantes - Nantes
- Centre Antoine Lacassagne - Nice
- CHU Haut-Leveque, Service d'Hematologie Clinique et Therapie Cellulaire - Pessac
- Centre Hospitalier Lyon-Sud, Service d'Hematologie - Pierre-Bénite
- Centre Henri Becquerel - Rouen
- Institut Universitaire du Cancer Toulouse Oncopole - Toulouse
California
- Moores UC San Diego Cancer Center - La Jolla
Florida
- Mayo Clinic - Jacksonville
Georgia
- Northside Hospital - Atlanta
Illinois
- The University of Chicago Medicine - Chicago
Michigan
- University of Michigan - Ann Arbor
Ohio
- The Ohio State University Wexner Medical Center and James Cancer Hospital - Columbus
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2016-10 |
| Est. Completion | 2024-04 |
| Phase | Phase 1 |
What the finished NCT02924402 record still lists
NCT02924402 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (15% lower).
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which XmAb13676 is the first listed.
NCT02924402 names 20 study sites across 11 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02924402 about?
NCT02924402 is a clinical study titled "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies". The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
What is the current status of trial NCT02924402?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2016-10. Estimated completion is 2024-04.
What conditions does trial NCT02924402 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, B Cell Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT02924402?
The interventions under investigation include: XmAb13676 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02924402?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02924402 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02924402's enrollment target sits among peer trials
154 49th of 187 higher than 138 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05599750 · 154 participants · NA
Suture Repair vs Mesh Repair for Incisional Hernia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia